Management of Non-Melanoma Skin Cancer in Solid Organ Transplant Recipients

Specchio, Francesca; Saraceno, Rosita; Chimenti, Sergio; Nisticò, Salvatore

doi:10.1177/039463201402700104

Cited by 28 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We decided to start infliximab in our patient as he had already undergone etanercept therapy during childhood. Furthermore, some cases of mucocutaneous BD have been successfully treated with infliximab, as reported in recent literature (9)(10)(11)(12), with results that are comparable to other dermatosis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22).…”

Section: Discussionsupporting

confidence: 53%

An Incomplete Form of Childhood Behçet's Disease Treated with Infliximab

Caporuscio

Pranteda

Nisticò

et al. 2014

Int J Immunopathol Pharmacol

Self Cite

View full text Add to dashboard Cite

Behçet's disease (BD) is a multi-systemic vasculitis characterized by the possible presence of cutaneous, ocular, articular and neurological manifestations. In this report, we examine the case of a fifteen-year old boy with an incomplete form of juvenile Behçet's disease which began with joint involvement and developed into a complete form only after several years. The patient showed a rapid response to anti-TNF-alpha (infliximab) with an improvement of mucocutaneous lesions (oral and genital ulcers, pseudofolliculitis) and arthritis.

show abstract

Section: Discussionsupporting

confidence: 53%

An Incomplete Form of Childhood Behçet's Disease Treated with Infliximab

Caporuscio

Pranteda

Nisticò

et al. 2014

Int J Immunopathol Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Reduction of immunosuppression may also be a reasonable adjuvant management strategy for transplant recipients with multiple, recurrent or life‐threatening skin cancers . Changing to a mammalian target‐of‐rapamycin inhibitor‐based immunosuppressive regime may also be beneficial for reducing the incidence of NMSC in this patient group …”

Section: Treatmentmentioning

confidence: 99%

Management of squamous cell and basal cell carcinomas of the head and neck with perineural invasion

et al. 2015

View full text Add to dashboard Cite

Perineural invasion (PNI) occurring in non-melanoma skin cancers (NMSC) is associated with an increased risk of locoregional recurrence and reduced disease-free survival. This necessitates early and accurate diagnosis, appropriate risk-stratification and a clear management strategy. The diagnosis of PNI is based on careful clinical assessment, imaging and histopathology. Surgery, preferably with margin control, and definitive or adjuvant radiotherapy (ART) are established treatment strategies for PNI. Clinical uncertainty remains over the role of ART in incidental PNI. This review synthesises current literature to ascertain which clinicopathological features impart a higher risk to individuals with PNI in NMSC, in order to provide treatment algorithms, including the identification of patient subsets that are most likely to benefit from ART. This includes those with extratumoural PNI, involvement of larger-calibre nerves, tumour invasion beyond dermis, recurrent tumour or diffuse intratumoural spread. Patients with clinical PNI may be optimally managed by a multidisciplinary head and neck cancer service that is best placed to offer skull base surgery and intensity-modulated radiation therapy (IMRT). The management options presented are stratified by histological subtype and a new classification of PNI into low-risk, medium-risk and high-risk groups.

show abstract

“…6–9 NMSC is the most frequent cancer observed in solid organ transplant recipients. 10 Considering the well-established elevated risk of NMSC in the immunocompromised populations, HIV-infected individuals may be also vulnerable to NMSC. 4,11,12…”

Section: Introductionmentioning

confidence: 99%

The risk of non-melanoma skin cancer in HIV-infected patients: new data and meta-analysis

2015

View full text Add to dashboard Cite

The role of HIV/AIDS in non-melanoma skin cancer (NMSC) is not well defined. We sought to update the evidence of the association between HIV/AIDS and risk of NMSC by gender and antiretroviral therapy (ART). We searched MEDLINE and EMBASE on 29 February 2014. Standardised incidence ratios with corresponding 95% confidence intervals were extracted and combined using generic inverse variance methods assuming a random effects model. Six studies including 78,794 patients with HIV/AIDS fulfilled the inclusion criteria. Analysis of all studies showed that HIV/AIDS was associated with an increased risk of NMSC (standardised incidence ratio 2.76; 95% confidence interval 2.55-2.98). The standardised incidence ratios of NMSC were 3.63 (1.08-12.22) for men and 2.18 (1.24-3.83) for women with HIV/AIDS, respectively. In analysis stratified by ART, we found that individuals receiving ART had lower risk of developing NMSC than individuals who had not received ART (standardised incidence ratio, 95% confidence interval; 1.95 [1.10-3.47] versus 2.11 [1.44-3.12]). HIV/AIDS is associated with an increased risk of NMSC in both male and female patients. The use of ART appears to be beneficial in protecting against the development of NMSC.

show abstract

Management of Non-Melanoma Skin Cancer in Solid Organ Transplant Recipients

Cited by 28 publications

References 22 publications

An Incomplete Form of Childhood Behçet's Disease Treated with Infliximab

An Incomplete Form of Childhood Behçet's Disease Treated with Infliximab

Management of squamous cell and basal cell carcinomas of the head and neck with perineural invasion

The risk of non-melanoma skin cancer in HIV-infected patients: new data and meta-analysis

Contact Info

Product

Resources

About